Show simple item record

dc.contributor.authorSmyth, Elizabeth C
dc.contributor.authorLagergren, Jesper
dc.contributor.authorFitzgerald, Rebecca
dc.contributor.authorLordick, Florian
dc.contributor.authorShah, Manish A
dc.contributor.authorLagergren, Pernilla
dc.contributor.authorCunningham, David
dc.date.accessioned2018-09-05T12:49:40Z
dc.date.available2018-09-05T12:49:40Z
dc.date.issued2017-07-27
dc.identifier.issn2056-676X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/279600
dc.description.abstractOesophageal cancer is the sixth most common cause of cancer-related death worldwide and is therefore a major global health challenge. The two major subtypes of oesophageal cancer are oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC), which are epidemiologically and biologically distinct. OSCC accounts for 90% of all cases of oesophageal cancer globally and is highly prevalent in the East, East Africa and South America. OAC is more common in developed countries than in developing countries. Preneoplastic lesions are identifiable for both OSCC and OAC; these are frequently amenable to endoscopic ablative therapies. Most patients with oesophageal cancer require extensive treatment, including chemotherapy, chemoradiotherapy and/or surgical resection. Patients with advanced or metastatic oesophageal cancer are treated with palliative chemotherapy; those who are human epidermal growth factor receptor 2 (HER2)-positive may also benefit from trastuzumab treatment. Immuno-oncology therapies have also shown promising early results in OSCC and OAC. In this Primer, we review state-of-the-art knowledge on the biology and treatment of oesophageal cancer, including screening, endoscopic ablative therapies and emerging molecular targets, and we discuss best practices in chemotherapy, chemoradiotherapy, surgery and the maintenance of patient quality of life.
dc.format.mediumElectronic
dc.languageeng
dc.subjectHumans
dc.subjectAdenocarcinoma
dc.subjectCarcinoma, Squamous Cell
dc.subjectEsophageal Neoplasms
dc.subjectReceptor, erbB-2
dc.subjectEndoscopy, Digestive System
dc.subjectPrognosis
dc.subjectTreatment Outcome
dc.subjectSurvival Rate
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectAfrica, Eastern
dc.subjectSouth America
dc.subjectFemale
dc.subjectMale
dc.subjectChemoradiotherapy
dc.subjectTrastuzumab
dc.subjectAntineoplastic Agents, Immunological
dc.subjectEsophageal Squamous Cell Carcinoma
dc.titleOesophageal cancer.
dc.typeArticle
prism.publicationDate2017
prism.publicationNameNat Rev Dis Primers
prism.startingPage17048
prism.volume3
dc.identifier.doi10.17863/CAM.26971
dcterms.dateAccepted2017-06-08
rioxxterms.versionofrecord10.1038/nrdp.2017.48
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-07-27
dc.contributor.orcidFitzgerald, Rebecca [0000-0002-3434-3568]
dc.identifier.eissn2056-676X
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCancer Research Uk (None)
cam.issuedOnline2017-07-27
rioxxterms.freetoread.startdate2018-07-27


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record